reboxetine has been researched along with fluoxetine in 81 studies
| Studies (reboxetine) | Trials (reboxetine) | Recent Studies (post-2010) (reboxetine) | Studies (fluoxetine) | Trials (fluoxetine) | Recent Studies (post-2010) (fluoxetine) |
|---|---|---|---|---|---|
| 626 | 193 | 184 | 10,100 | 1,663 | 3,263 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 7 (8.64) | 18.2507 |
| 2000's | 37 (45.68) | 29.6817 |
| 2010's | 29 (35.80) | 24.3611 |
| 2020's | 8 (9.88) | 2.80 |
| Authors | Studies |
|---|---|
| Bosc, M; Dubini, A; Polin, V | 3 |
| Massana, J | 1 |
| Dantchev, N; Widlöcher, DJ | 1 |
| Montgomery, SA | 1 |
| Burrows, GD; Massana, J; Möller, HJ; Montenegro, RM | 1 |
| Tanum, L | 1 |
| Healy, D | 1 |
| Schatzberg, AF | 1 |
| Arcelus, A; Barr, CE; Birnbaum, H; Greenberg, P; Rowland, C; Venditti, LN; Williamson, T | 1 |
| Duman, RS; Eisch, AJ; Malberg, JE; Nestler, EJ | 1 |
| Benazzi, F | 1 |
| Andreoli, V; Caillard, V; Deo, RS; Rybakowski, JK; Versiani, M | 1 |
| Brown, MT; Clayton, AH; Ferguson, JM; Filipiak-Reisner, JK; Schwartz, GE; Zajecka, J | 1 |
| Fava, M; McGrath, PJ; Sheu, WP | 1 |
| Cortizo, L; García, N; Innerárity, A; Labeaga, L; Mosquera, R; Orjales, A; Pumar, MC; Toledo, A | 1 |
| Cryan, JF; Dalvi, A; Friedland, JC; Hirsch, BR; Jin, SH; Lucki, I; O'Leary, OF; Ouyang, M; Page, ME; Thomas, SA | 1 |
| Held, K; Kuenzel, HE; Murck, H; Steiger, A; Ziegenbein, M | 1 |
| Carey, GJ; Gold, LH; Nielsen, DM | 1 |
| Dziedzicka-Wasylewska, M; Filip, M; Inan, SY; Przegaliński, E; Wydra, K | 1 |
| Endo, S; Habara, T; Hamamura, T; Kuroda, S; Lee, Y; Miki, M; Miyata, S; Oka, T; Taoka, H | 1 |
| Leon, AC; Nelson, JC; Portera, L | 2 |
| Biegon, A; Ding, YS; Fowler, J; Lin, KS; Logan, J; Pareto, D | 1 |
| Benveniste, H; Carter, P; Ding, YS; Lin, KS; Logan, J | 1 |
| Cryan, JF; Lucki, I; Page, ME | 1 |
| Coyne, J | 1 |
| Blackburn-Munro, G; Nielsen, AN; Pedersen, LH | 1 |
| Banaschewski, T; Bock, N; Hüther, G; Moll, GH; Quentin, DJ; Rothenberger, A | 1 |
| Amore, M; Di Sarro, R; Gallassi, R; Morreale, A | 1 |
| Falcon, R; González, I; Jorquera, F; Monari, M; Orrego, F; Sandoval, M; Sandoval, S; Vargas, F; Wyneken, U | 1 |
| Arango, V; Kumar, JSD; Majo, VJ; Mann, JJ; Milak, MS; Parsey, RV; Prabhakaran, J; Severance, AJ; Simpson, NR; Van Heertum, RL | 1 |
| Bechtholt, AJ; Crowley, JJ; Hill, TE; Lucki, I; O'Leary, OF; Page, ME | 1 |
| Barbiero, VS; Longordo, F; Luccini, E; Pittaluga, A; Popoli, M; Racagni, G; Raiteri, L; Raiteri, M | 1 |
| Fujibayashi, Y; Kanegawa, N; Kawashima, H; Kiyono, Y; Kuge, Y; Saji, H; Sugita, T; Ueda, M | 1 |
| Akar, FY; Erden, BF; Komsuoğlu, FI; Mutlu, O; Tanyeri, P; Ulak, G | 1 |
| Donnici, L; Musazzi, L; Popoli, M; Racagni, G; Tardito, D; Tiraboschi, E | 1 |
| Aubin, N; Avenet, P; Bougault, I; Busch, S; Chen, Y; Claustre, Y; Desvignes, C; Didier, M; Keane, P; Le Fur, G; Leonetti, M; Oury-Donat, F; Palejwala, V; Rouquier, L; Santucci, V; Scatton, B; Steinberg, R; Tocci, M; Yamdagni, P | 1 |
| Blicharska, E; Brański, P; Cichy, A; Dybała, M; Nowak, G; Pilc, A; Piotrowska, A; Poleszak, E; Pomierny-Chamioło, L; Siwek, A; Szewczyk, B; Wlaź, P; Wróbel, A | 1 |
| Babbs, AJ; Chatfield, RE; Krülle, TM; McCormack, JG; Provost, D; Thomas, GH; Widdowson, PS | 1 |
| Barbon, A; Barlati, S; Cattaneo, A; Gennarelli, M; Musazzi, L; Popoli, M; Racagni, G; Tardito, D | 1 |
| Aburakawa, Y; Aizawa, H; Hasebe, N; Kwak, S; Sawada, J; Yamashita, T | 1 |
| Fisar, Z; Hroudová, J; Raboch, J | 1 |
| Farajian-Mashhadi, F; Javid, FA; Naylor, RJ | 1 |
| Barbon, A; Barlati, S; Caracciolo, L; Gennarelli, M; La Via, L; Mallei, A; Musazzi, L; Orlandi, C; Popoli, M; Racagni, G; Tardito, D | 1 |
| Chapman, A; Delivuk, M; Gartlehner, G; Gaynes, BN; Kaminski, A; Thaler, K | 1 |
| Baj, G; D'Alessandro, V; Langone, F; Mallei, A; Musazzi, L; Popoli, M; Sartori, CR; Sciancalepore, M; Tardito, D; Tongiorgi, E | 1 |
| Barbato, A; Bortolotti, A; D'Avanzo, B; Fortino, I; Franchi, C; Merlino, L; Nobili, A; Parabiaghi, A; Tettamanti, M | 1 |
| Carson, RE; Ding, YS; Fan, X; Gallezot, JD; Lin, SF; Mulnix, T; Sherwin, RS; Weinzimmer, D; Yeckel, CW | 1 |
| Falk, A; Johansson, D; Marcus, MM; Svensson, TH | 1 |
| Charoenphandhu, J; Charoenphandhu, N; Krishnamra, N; Lapmanee, S; Teerapornpuntakit, J | 1 |
| Berrocoso, E; Mico, JA; Miguelez, C; Ugedo, L | 1 |
| Anderson, MH; Munafò, MR; Robinson, ES | 1 |
| Charoenphandhu, J; Charoenphandhu, N; Lapmanee, S | 1 |
| Cadeddu, R; Carboni, E; Ibba, M; Sadile, A | 1 |
| Domenici, E; Ieraci, A; Musazzi, L; Popoli, M; Racagni, G; Rimland, JM | 1 |
| Dudka, J; Kasperek, R; Nowak, G; Poleszak, E; Serefko, A; Wlaź, A; Wlaź, P; Wośko, S; Wróbel, A | 1 |
| Gray, VC; Hughes, RN | 1 |
| Filipek, B; Olczyk, A; Pytka, K; Rapacz, A; Sapa, J; Waszkielewicz, A; Zygmunt, M | 1 |
| Ampuero, E; Cavada, G; Diaz-Veliz, G; Luarte, A; Rubio, FJ; Santibañez, M; Toledo, J; Varas-Godoy, M; Wyneken, U | 1 |
| Aydin, A; Gulec, M; Ozcan, H; Yucel, A; Yucel, N | 1 |
| Cao, YJ; Hendrix, CW; Kaplin, AI; Rahn, KA | 1 |
| Gouaux, E; Penmatsa, A; Wang, KH | 1 |
| Beltran, E; Domínguez-Andrés, J; Erburu, M; Mai, A; Muñoz-Cobo, I; Puerta, E; Suzuki, T; Tordera, RM; Valente, S | 1 |
| Rahman, S; Roni, MA | 1 |
| Harro, J; Kõiv, K; O'Leary, A; Raudkivi, K | 1 |
| Bove, M; Mhillaj, E; Morgese, MG; Schiavone, S; Trabace, L; Tucci, P | 1 |
| Jiao, Y; Liang, Y; Lin, J; Qu, H; Sun, Y; Xu, J; Zhao, C | 1 |
| Casarotto, PC; Crestani, CC; Diniz, CRAF; Joca, SRL; Pereira, VS; Rodrigues, M | 1 |
| Cirilli, R; Erburu, MM; Mai, A; Muñoz-Cobo, I; Puerta, E; Tordera, RM; Valente, S; Zwergel, C | 1 |
| Buchanan, GF; Dayton, KG; Kruse, SW; Purnell, BS; Rosner, JI | 1 |
| Chapman, A; Gartlehner, G; Gaynes, BN; Nussbaumer-Streit, B; Probst, T; Sönnichsen, A; Thaler, K; Winkler, D | 1 |
| Chmielarz, P; Chorązka, K; Kowalska, M; Kuśmierczyk, J; Nalepa, I; Rafa-Zabłocka, K; Satała, G | 1 |
| Koziorowski, M; Mytych, J; Sołek, P; Tabęcka-Łonczyńska, A | 1 |
| Agarwal, SM; Ahsan, ZA; Cohn, T; Duncan, MJ; Faulkner, GEJ; Hahn, M; Lockwood, JT; Remington, G; Stogios, N; Takeuchi, H; Taylor, VH | 1 |
| Hatano, M; Ikuta, T; Iwata, N; Kishi, T; Matsuda, Y; Okuya, M; Sakuma, K | 1 |
| Bannister, K; Kozak, D; Mogil, JS; Nemoto, W; Sotocinal, SG; Tansley, S | 1 |
| Keidan, L; Pick, CG; Schreiber, S | 1 |
| Barbui, C; Bighelli, I; Caldwell, DM; Cipriani, A; Davies, SJ; Dawson, S; Dias, S; Furukawa, TA; Guaiana, G; Imai, H; Koesters, M; Meader, N; Pompoli, A; Robertson, L; Tajika, A | 1 |
9 review(s) available for reboxetine and fluoxetine
| Article | Year |
|---|---|
Chairman's overview. The place of reboxetine in antidepressant therapy.
Topics: Adrenergic Uptake Inhibitors; Adult; Age Factors; Aged; Antidepressive Agents, Tricyclic; Clinical Trials as Topic; Depressive Disorder; Fluoxetine; Humans; Morpholines; Reboxetine; Severity of Illness Index; Social Adjustment; Treatment Outcome | 1998 |
Reboxetine: tolerability and safety profile in patients with major depression.
Topics: Adrenergic Uptake Inhibitors; Age Factors; Antidepressive Agents; Cytochrome P-450 Enzyme System; Depressive Disorder, Major; Drug Interactions; Fluoxetine; Humans; Imipramine; Morpholines; Multicenter Studies as Topic; Randomized Controlled Trials as Topic; Reboxetine; Therapeutic Equivalency | 2000 |
Reboxetine: its effects as measured by the Social Adaptation Self-evaluation Scale.
Topics: Adrenergic Uptake Inhibitors; Adult; Antidepressive Agents; Depressive Disorder, Major; Female; Fluoxetine; Humans; Male; Middle Aged; Morpholines; Multicenter Studies as Topic; Psychiatric Status Rating Scales; Randomized Controlled Trials as Topic; Reboxetine; Selective Serotonin Reuptake Inhibitors; Social Adjustment; Therapeutic Equivalency; Treatment Outcome | 2000 |
Clinical efficacy of reboxetine in major depression.
Topics: Adrenergic Uptake Inhibitors; Antidepressive Agents, Tricyclic; Controlled Clinical Trials as Topic; Depressive Disorder; Fluoxetine; Humans; Imipramine; Morpholines; Norepinephrine; Panic Disorder; Placebos; Reboxetine; Selective Serotonin Reuptake Inhibitors; Treatment Outcome | 2000 |
Second-generation antidepressants for seasonal affective disorder.
Topics: Adult; Antidepressive Agents, Second-Generation; Citalopram; Duloxetine Hydrochloride; Female; Fluoxetine; Humans; Male; Morpholines; Phototherapy; Randomized Controlled Trials as Topic; Reboxetine; Seasonal Affective Disorder; Thiophenes | 2011 |
Second-generation antidepressants for treatment of seasonal affective disorder.
Topics: Adult; Antidepressive Agents, Second-Generation; Bias; Citalopram; Duloxetine Hydrochloride; Female; Fluoxetine; Humans; Male; Morpholines; Observational Studies as Topic; Phototherapy; Placebos; Quality of Life; Randomized Controlled Trials as Topic; Reboxetine; Seasonal Affective Disorder; Thiophenes; Treatment Outcome | 2021 |
Pharmacological interventions for prevention of weight gain in people with schizophrenia.
Topics: Antipsychotic Agents; Betahistine; Famotidine; Fluoxetine; Humans; Melatonin; Metformin; Nausea; Nizatidine; Ranitidine; Reboxetine; Schizophrenia; Topiramate; Weight Gain | 2022 |
Antidepressants for the treatment of adults with major depressive disorder in the maintenance phase: a systematic review and network meta-analysis.
Topics: Adult; Amitriptyline; Antidepressive Agents; Citalopram; Depressive Disorder, Major; Desvenlafaxine Succinate; Duloxetine Hydrochloride; Female; Fluoxetine; Fluvoxamine; Humans; Mirtazapine; Network Meta-Analysis; Paroxetine; Randomized Controlled Trials as Topic; Reboxetine; Sertraline; Venlafaxine Hydrochloride; Vortioxetine | 2023 |
Pharmacological treatments in panic disorder in adults: a network meta-analysis.
Topics: Adult; Alprazolam; Antidepressive Agents; Antidepressive Agents, Tricyclic; Benzodiazepines; Clomipramine; Clonazepam; Desipramine; Diazepam; Fluoxetine; Humans; Network Meta-Analysis; Panic Disorder; Paroxetine; Reboxetine; Selective Serotonin Reuptake Inhibitors; Serotonin and Noradrenaline Reuptake Inhibitors; Venlafaxine Hydrochloride | 2023 |
12 trial(s) available for reboxetine and fluoxetine
| Article | Year |
|---|---|
Do noradrenaline and serotonin differentially affect social motivation and behaviour?
Topics: Adrenergic Uptake Inhibitors; Adult; Antidepressive Agents; Depressive Disorder; Double-Blind Method; Female; Fluoxetine; Humans; Male; Morpholines; Prospective Studies; Psychiatric Status Rating Scales; Reboxetine; Selective Serotonin Reuptake Inhibitors; Social Behavior | 1997 |
Development and validation of a social functioning scale, the Social Adaptation Self-evaluation Scale.
Topics: Adrenergic Uptake Inhibitors; Adult; Antidepressive Agents; Depressive Disorder; Double-Blind Method; Fluoxetine; Humans; Middle Aged; Morpholines; Psychiatric Status Rating Scales; Reboxetine; Reproducibility of Results; Selective Serotonin Reuptake Inhibitors; Social Behavior; Surveys and Questionnaires | 1997 |
Noradrenaline-selective versus serotonin-selective antidepressant therapy: differential effects on social functioning.
Topics: Adolescent; Adrenergic Uptake Inhibitors; Adult; Aged; Antidepressive Agents, Second-Generation; Depressive Disorder; Double-Blind Method; Female; Fluoxetine; Humans; Male; Middle Aged; Morpholines; Norepinephrine; Psychiatric Status Rating Scales; Reboxetine; Selective Serotonin Reuptake Inhibitors; Social Behavior | 1997 |
Reboxetine versus fluoxetine: an overview of efficacy and tolerability.
Topics: Adrenergic Uptake Inhibitors; Antidepressive Agents, Tricyclic; Depressive Disorder; Double-Blind Method; Fluoxetine; Humans; Morpholines; Motivation; Placebos; Psychiatric Status Rating Scales; Reboxetine; Selective Serotonin Reuptake Inhibitors; Self Concept; Severity of Illness Index; Treatment Outcome | 1998 |
Reboxetine: a double-blind comparison with fluoxetine in major depressive disorder.
Topics: Adult; Antidepressive Agents; Depressive Disorder; Double-Blind Method; Female; Fluoxetine; Humans; Male; Middle Aged; Morpholines; Reboxetine | 1999 |
Reboxetine, a new noradrenaline selective antidepressant, is at least as effective as fluoxetine in the treatment of depression.
Topics: Adrenergic Uptake Inhibitors; Adult; Analysis of Variance; Antidepressive Agents; Chi-Square Distribution; Confidence Intervals; Depressive Disorder, Major; Double-Blind Method; Female; Fluoxetine; Humans; Male; Middle Aged; Morpholines; Prospective Studies; Psychiatric Status Rating Scales; Reboxetine; Selective Serotonin Reuptake Inhibitors | 2002 |
Lack of sexual dysfunction with the selective noradrenaline reuptake inhibitor reboxetine during treatment for major depressive disorder.
Topics: Adolescent; Adult; Aged; Antidepressive Agents; Antidepressive Agents, Second-Generation; Depressive Disorder; Double-Blind Method; Female; Fluoxetine; Humans; Male; Middle Aged; Morpholines; Patient Compliance; Patient Satisfaction; Reboxetine; Sexual Dysfunction, Physiological | 2003 |
Switching to reboxetine: an efficacy and safety study in patients with major depressive disorder unresponsive to fluoxetine.
Topics: Adolescent; Adult; Aged; Antidepressive Agents; Depressive Disorder, Major; Drug Resistance; Female; Fluoxetine; Humans; Male; Middle Aged; Morpholines; Psychiatric Status Rating Scales; Reboxetine; Social Behavior | 2003 |
Reboxetine induces similar sleep-EEG changes like SSRI's in patients with depression.
Topics: Adrenergic Uptake Inhibitors; Adult; Aged; Depressive Disorder, Major; Electroencephalography; Female; Fluoxetine; Humans; Male; Middle Aged; Morpholines; Reboxetine; Selective Serotonin Reuptake Inhibitors; Sleep Initiation and Maintenance Disorders; Sleep Stages; Wakefulness | 2004 |
Are there differences in the symptoms that respond to a selective serotonin or norepinephrine reuptake inhibitor?
Topics: Adrenergic Uptake Inhibitors; Adult; Depression; Double-Blind Method; Female; Fluoxetine; Humans; Male; Middle Aged; Morpholines; Placebos; Psychiatric Status Rating Scales; Reboxetine; Selective Serotonin Reuptake Inhibitors; Treatment Outcome | 2005 |
Residual symptoms in depressed patients after treatment with fluoxetine or reboxetine.
Topics: Adrenergic Uptake Inhibitors; Adult; Anxiety Disorders; Depression; Depressive Disorder; Double-Blind Method; Female; Fluoxetine; Humans; Libido; Male; Morpholines; Norepinephrine; Psychiatric Status Rating Scales; Reboxetine; Severity of Illness Index; Sexual Dysfunctions, Psychological; Sleep Wake Disorders; Treatment Outcome | 2005 |
Memory impairment in patients with late-onset major depression: the effect of antidepressant therapy.
Topics: Adolescent; Adult; Age of Onset; Depressive Disorder, Major; Female; Fluoxetine; Humans; Male; Memory Disorders; Middle Aged; Morpholines; Neuropsychological Tests; Reboxetine; Selective Serotonin Reuptake Inhibitors; Severity of Illness Index | 2006 |
60 other study(ies) available for reboxetine and fluoxetine
| Article | Year |
|---|---|
The measurement of retardation in depression.
Topics: Adrenergic Uptake Inhibitors; Adult; Depressive Disorder; Female; Fluoxetine; Humans; Male; Middle Aged; Morpholines; Motor Activity; Psychiatric Status Rating Scales; Psychometrics; Psychomotor Agitation; Psychomotor Disorders; Psychomotor Performance; Reboxetine; Speech | 1998 |
The impact of antidepressant use on social functioning: reboxetine versus fluoxetine.
Topics: Adrenergic Uptake Inhibitors; Adult; Depressive Disorder; Female; Fluoxetine; Humans; Male; Morpholines; Reboxetine; Selective Serotonin Reuptake Inhibitors; Severity of Illness Index; Social Behavior; Treatment Outcome | 2000 |
Novel antidepressant strategies to optimize outcome.
Topics: Adrenergic Uptake Inhibitors; Antidepressive Agents; Depressive Disorder; Fluoxetine; Humans; Morpholines; Norepinephrine; Personality Inventory; Reboxetine; Severity of Illness Index; Social Adjustment; Treatment Outcome | 2000 |
Chronic antidepressant treatment increases neurogenesis in adult rat hippocampus.
Topics: Animals; Antidepressive Agents; Antigens, Differentiation; Bromodeoxyuridine; Cell Count; Cell Division; Cell Survival; Fluorescent Antibody Technique; Fluoxetine; Hippocampus; Male; Morpholines; Neurons; Rats; Rats, Sprague-Dawley; Reboxetine; Tranylcypromine | 2000 |
Urinary retention with reboxetine-fluoxetine combination in a young man.
Topics: Adult; Antidepressive Agents; Depressive Disorder, Major; Drug Therapy, Combination; Fluoxetine; Humans; Male; Morpholines; Reboxetine; Urinary Retention | 2000 |
Syntheses and binding studies of new [(aryl)(aryloxy)methyl]piperidine derivatives and related compounds as potential antidepressant drugs with high affinity for serotonin (5-HT) and norepinephrine (NE) transporters.
Topics: Adrenergic Uptake Inhibitors; Animals; Antidepressive Agents; Brain; Carrier Proteins; Fluoxetine; In Vitro Techniques; Male; Membrane Glycoproteins; Membrane Transport Proteins; Morpholines; Nerve Tissue Proteins; Norepinephrine; Norepinephrine Plasma Membrane Transport Proteins; Piperidines; Radioligand Assay; Rats; Rats, Wistar; Reboxetine; Receptor, Serotonin, 5-HT1A; Receptor, Serotonin, 5-HT2A; Selective Serotonin Reuptake Inhibitors; Serotonin; Serotonin Plasma Membrane Transport Proteins; Stereoisomerism; Structure-Activity Relationship; Symporters | 2003 |
Norepinephrine-deficient mice lack responses to antidepressant drugs, including selective serotonin reuptake inhibitors.
Topics: Animals; Antidepressive Agents; Citalopram; Depression; Desipramine; Dopamine beta-Hydroxylase; Droxidopa; Fluoxetine; Gene Deletion; Mice; Morpholines; Norepinephrine; Paroxetine; Reboxetine; Selective Serotonin Reuptake Inhibitors; Sertraline; Tail | 2004 |
Antidepressant-like activity of corticotropin-releasing factor type-1 receptor antagonists in mice.
Topics: Animals; Antidepressive Agents; Clorgyline; Desipramine; Dose-Response Relationship, Drug; Fluoxetine; Hindlimb Suspension; Male; Mice; Morpholines; Motor Activity; Paroxetine; Pyrazoles; Pyrimidines; Pyrroles; Reboxetine; Receptors, Corticotropin-Releasing Hormone; Selegiline; Swimming; Tranylcypromine; Triazines | 2004 |
Opioid and monoamine systems mediate the discriminative stimulus of tramadol in rats.
Topics: Adrenergic Uptake Inhibitors; Analgesics, Opioid; Animals; Antidepressive Agents; Biogenic Monoamines; Conditioning, Operant; Cyclohexanols; Cyclopropanes; Discrimination, Psychological; Dopamine Uptake Inhibitors; Dose-Response Relationship, Drug; Drug Synergism; Fluoxetine; Male; Milnacipran; Morphine; Morpholines; Naloxone; Narcotic Antagonists; Nomifensine; Rats; Rats, Wistar; Reboxetine; Receptors, Opioid, mu; Selective Serotonin Reuptake Inhibitors; Sodium Chloride; Tramadol; Venlafaxine Hydrochloride | 2004 |
Contrasting Fos expression induced by acute reboxetine and fluoxetine in the rat forebrain: neuroanatomical substrates for the antidepressant effect.
Topics: Animals; Dose-Response Relationship, Drug; Fluoxetine; Frontal Lobe; Gene Expression; Genes, fos; Immunohistochemistry; Male; Morpholines; Nucleus Accumbens; Photomicrography; Rats; Rats, Wistar; Reboxetine | 2005 |
Modeling and analysis of PET studies with norepinephrine transporter ligands: the search for a reference region.
Topics: Animals; Brain; Carbon Radioisotopes; Fluorine Radioisotopes; Fluoxetine; Ligands; Morpholines; Papio; Positron-Emission Tomography; Raclopride; Reboxetine | 2005 |
Comparative evaluation of positron emission tomography radiotracers for imaging the norepinephrine transporter: (S,S) and (R,R) enantiomers of reboxetine analogs ([11C]methylreboxetine, 3-Cl-[11C]methylreboxetine and [18F]fluororeboxetine), (R)-[11C]nisox
Topics: Adrenergic Uptake Inhibitors; Animals; Autoradiography; Benzopyrans; Binding, Competitive; Brain; Brain Chemistry; Brain Mapping; Carbon Radioisotopes; Chromatography, High Pressure Liquid; Dose-Response Relationship, Drug; Drug Interactions; Evaluation Studies as Topic; Fluorine Radioisotopes; Fluoxetine; Image Processing, Computer-Assisted; Magnetic Resonance Imaging; Maprotiline; Mice; Morpholines; Nordefrin; Norepinephrine Plasma Membrane Transport Proteins; Papio; Positron-Emission Tomography; Protein Binding; Radioligand Assay; Reboxetine; Symporters; Time Factors; Tissue Distribution | 2005 |
Differential behavioral effects of the antidepressants reboxetine, fluoxetine, and moclobemide in a modified forced swim test following chronic treatment.
Topics: Animals; Antidepressive Agents; Behavior, Animal; Fluoxetine; Male; Moclobemide; Morpholines; Rats; Rats, Sprague-Dawley; Reboxetine; Swimming | 2005 |
Lessons in conflict of interest: the construction of the martyrdom of David Healy and the dilemma of bioethics.
Topics: Academies and Institutes; Antidepressive Agents, Second-Generation; Bioethics; Canada; Clinical Trials as Topic; Conflict of Interest; Disclosure; Drug Industry; Editorial Policies; Ethicists; Ethics, Research; Expert Testimony; Fluoxetine; Fraud; Humans; Journalism; Mental Health; Morpholines; Periodicals as Topic; Professional Misconduct; Publication Bias; Reboxetine; Research Support as Topic; Selective Serotonin Reuptake Inhibitors; Suicide; United States; United States Food and Drug Administration | 2005 |
Anti-nociception is selectively enhanced by parallel inhibition of multiple subtypes of monoamine transporters in rat models of persistent and neuropathic pain.
Topics: Amines; Analgesics; Analysis of Variance; Animals; Antidepressive Agents; Behavior, Animal; Bupropion; Constriction; Cyclohexanecarboxylic Acids; Disease Models, Animal; Dose-Response Relationship, Drug; Fluoxetine; Gabapentin; gamma-Aminobutyric Acid; Male; Morpholines; Motor Activity; Neurotransmitter Uptake Inhibitors; Pain; Pain Measurement; Pain Threshold; Rats; Rats, Sprague-Dawley; Reboxetine; Rotarod Performance Test; Spinal Cord Injuries; Vesicular Monoamine Transport Proteins | 2005 |
Very early treatment with fluoxetine and reboxetine causing long-lasting change of the serotonin but not the noradrenaline transporter in the frontal cortex of rats.
Topics: Animals; Drug Administration Schedule; Fluoxetine; Frontal Lobe; Morpholines; Norepinephrine Plasma Membrane Transport Proteins; Rats; Rats, Wistar; Reboxetine; Selective Serotonin Reuptake Inhibitors; Serotonin; Symporters; Time Factors | 2005 |
Clinically relevant doses of fluoxetine and reboxetine induce changes in the TrkB content of central excitatory synapses.
Topics: Animals; Antidepressive Agents; Blotting, Western; Brain; Brain-Derived Neurotrophic Factor; Dose-Response Relationship, Drug; Fluoxetine; Glutamic Acid; Immunoprecipitation; Male; Morpholines; Phosphotyrosine; rab5 GTP-Binding Proteins; Rats; Rats, Sprague-Dawley; Reboxetine; Receptor, trkB; Subcellular Fractions; Synapses; Time Factors | 2006 |
In vivo assessment of [11C]MRB as a prospective PET ligand for imaging the norepinephrine transporter.
Topics: Adrenergic Uptake Inhibitors; Animals; Carbon Radioisotopes; Diagnostic Imaging; Fluoxetine; Image Processing, Computer-Assisted; Kinetics; Ligands; Morpholines; Norepinephrine Plasma Membrane Transport Proteins; Papio; Positron-Emission Tomography; Reboxetine; Sensitivity and Specificity; Serotonin Plasma Membrane Transport Proteins; Time Factors | 2007 |
Depletion of serotonin and catecholamines block the acute behavioral response to different classes of antidepressant drugs in the mouse tail suspension test.
Topics: Adrenergic Uptake Inhibitors; Animals; Antidepressive Agents; Behavior, Animal; Brain; Citalopram; Desipramine; Dopamine; Fenclonine; Fluoxetine; Hindlimb Suspension; Male; Mice; Mice, Inbred C57BL; Morpholines; Norepinephrine; Reboxetine; Selective Serotonin Reuptake Inhibitors; Serotonin | 2007 |
Antidepressant treatments and function of glutamate ionotropic receptors mediating amine release in hippocampus.
Topics: alpha-Amino-3-hydroxy-5-methyl-4-isoxazolepropionic Acid; Amines; Animals; Antidepressive Agents; Corpus Striatum; Drug Interactions; Excitatory Amino Acid Agents; Fluoxetine; Gene Expression; Hippocampus; Male; Morpholines; N-Methylaspartate; Potassium; Rats; Rats, Sprague-Dawley; Reboxetine; Receptors, Glutamate; Synaptosomes; Time Factors; Tritium | 2007 |
Evaluation of radioiodinated (2S,alphaS)-2-(alpha-(2-iodophenoxy)benzyl)morpholine as a radioligand for imaging of norepinephrine transporter in the heart.
Topics: Animals; Binding, Competitive; Desipramine; Dopamine Plasma Membrane Transport Proteins; Dopamine Uptake Inhibitors; Fluoxetine; Heart; Iodine Radioisotopes; Isotope Labeling; Metabolic Clearance Rate; Morpholines; Norepinephrine; Norepinephrine Plasma Membrane Transport Proteins; Piperazines; Radioligand Assay; Radionuclide Imaging; Radiopharmaceuticals; Rats; Reboxetine; Selective Serotonin Reuptake Inhibitors; Serotonin Plasma Membrane Transport Proteins; Tissue Distribution | 2008 |
Neuronal NOS inhibitor 1-(2-trifluoromethylphenyl)-imidazole augment the effects of antidepressants acting via serotonergic system in the forced swimming test in rats.
Topics: Adrenergic Uptake Inhibitors; Animals; Antidepressive Agents; Antidepressive Agents, Tricyclic; Citalopram; Drug Interactions; Enzyme Inhibitors; Fluoxetine; Imidazoles; Male; Morpholines; Motor Activity; Nitric Oxide Synthase Type I; Rats; Rats, Wistar; Reboxetine; Selective Serotonin Reuptake Inhibitors; Serotonin; Swimming; Thiazepines | 2008 |
Time-dependent biphasic modulation of human BDNF by antidepressants in neuroblastoma cells.
Topics: Antidepressive Agents; Antidepressive Agents, Second-Generation; Brain-Derived Neurotrophic Factor; Cell Line, Tumor; Desipramine; Fluoxetine; Gene Expression Regulation, Neoplastic; Humans; Morpholines; Neuroblastoma; Reboxetine; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Time Factors | 2008 |
Effects of the beta3-adrenoceptor (Adrb3) agonist SR58611A (amibegron) on serotonergic and noradrenergic transmission in the rodent: relevance to its antidepressant/anxiolytic-like profile.
Topics: Action Potentials; Adrenergic beta-2 Receptor Agonists; Adrenergic beta-Agonists; Adrenergic Uptake Inhibitors; Analysis of Variance; Animals; Brain; Dose-Response Relationship, Drug; Drug Administration Routes; Drug Interactions; Fluoxetine; Male; Mice; Microdialysis; Morpholines; Motor Activity; Neurons; Norepinephrine; Rats; Reboxetine; Receptors, Adrenergic, beta-2; Selective Serotonin Reuptake Inhibitors; Serotonin; Tetrahydronaphthalenes; Tryptophan | 2008 |
The involvement of serotonergic system in the antidepressant effect of zinc in the forced swim test.
Topics: Adrenergic Uptake Inhibitors; Animals; Antidepressive Agents; Aspartic Acid; Citalopram; Fenclonine; Fluoxetine; Male; Mice; Morpholines; Motor Activity; Organometallic Compounds; Piperazines; Pyridines; Rats; Rats, Wistar; Reboxetine; Ritanserin; Selective Serotonin Reuptake Inhibitors; Serotonin; Serotonin Agents; Serotonin Antagonists; Swimming; Zinc Compounds | 2009 |
5-HT(1A) activation counteracts cardiovascular but not hypophagic effects of sibutramine in rats.
Topics: Adrenergic Uptake Inhibitors; Animals; Appetite Depressants; Blood Pressure; Cyclobutanes; Dose-Response Relationship, Drug; Eating; Fluoxetine; Heart Rate; Male; Models, Animal; Morpholines; Norepinephrine; Pyrimidines; Rats; Rats, Sprague-Dawley; Reboxetine; Receptor, Serotonin, 5-HT1A; Serotonin 5-HT1 Receptor Agonists; Triazines | 2009 |
Early raise of BDNF in hippocampus suggests induction of posttranscriptional mechanisms by antidepressants.
Topics: Adrenergic Uptake Inhibitors; Analysis of Variance; Animals; Antidepressive Agents; Brain-Derived Neurotrophic Factor; Fluoxetine; Hippocampus; Longitudinal Studies; Male; Morpholines; Rats; Rats, Sprague-Dawley; Reboxetine; RNA, Messenger; Selective Serotonin Reuptake Inhibitors; Statistics, Nonparametric; Transcription, Genetic | 2009 |
Effects of antidepressants on GluR2 Q/R site-RNA editing in modified HeLa cell line.
Topics: Adenosine Deaminase; Amitriptyline; Amyotrophic Lateral Sclerosis; Antidepressive Agents; Arginine; Cyclopropanes; Desipramine; Fluoxetine; Fluvoxamine; Glutamine; HeLa Cells; Humans; Imipramine; Milnacipran; Morpholines; Paroxetine; Reboxetine; Receptors, AMPA; RNA Editing; RNA-Binding Proteins; RNA, Messenger | 2009 |
Inhibition of monoamine oxidase activity by antidepressants and mood stabilizers.
Topics: Affect; Amitriptyline; Animals; Antidepressive Agents; Antimanic Agents; Benzodiazepines; Cerebral Cortex; Citalopram; Clorgyline; Cocaine; Cyclohexanols; Desipramine; Fluoxetine; Imipramine; In Vitro Techniques; Iproniazid; Lithium; Mianserin; Mirtazapine; Mitochondria; Moclobemide; Monoamine Oxidase; Monoamine Oxidase Inhibitors; Morpholines; Olanzapine; Pargyline; Reboxetine; Swine; Thiazepines; Valproic Acid; Venlafaxine Hydrochloride | 2010 |
The effect of fluoxetine on electrical field stimulation-induced responses in the isolated rat small intestine.
Topics: Adrenergic Uptake Inhibitors; Animals; Dose-Response Relationship, Drug; Electric Stimulation; Fluoxetine; Intestine, Small; Male; Morpholines; Muscle Contraction; Rats; Reboxetine; Selective Serotonin Reuptake Inhibitors | 2010 |
Antidepressant treatments change 5-HT2C receptor mRNA expression in rat prefrontal/frontal cortex and hippocampus.
Topics: Adrenergic Uptake Inhibitors; Animals; Down-Regulation; Fluoxetine; Frontal Lobe; Hippocampus; Male; Morpholines; Prefrontal Cortex; Rats; Rats, Sprague-Dawley; Reboxetine; Receptor, Serotonin, 5-HT2C; RNA Editing; Selective Serotonin Reuptake Inhibitors; Time Factors; Up-Regulation | 2011 |
Physical exercise and antidepressants enhance BDNF targeting in hippocampal CA3 dendrites: further evidence of a spatial code for BDNF splice variants.
Topics: Animals; Antidepressive Agents; Brain-Derived Neurotrophic Factor; CA3 Region, Hippocampal; Cells, Cultured; Dendrites; Fluoxetine; Male; Mice; Morpholines; Neurons; Norepinephrine; Physical Conditioning, Animal; Protein Isoforms; Rats; Rats, Sprague-Dawley; Reboxetine; Serotonin; Synaptic Transmission; Up-Regulation | 2012 |
The declining use of reboxetine in years 2000 to 2006: a pharmacoepidemiological comparative study.
Topics: Antidepressive Agents; Depression; Fluoxetine; Humans; Morpholines; Paroxetine; Pharmacoepidemiology; Practice Patterns, Physicians'; Publication Bias; Reboxetine; Selective Serotonin Reuptake Inhibitors | 2012 |
Ex vivo and in vivo evaluation of the norepinephrine transporter ligand [11C]MRB for brown adipose tissue imaging.
Topics: Adipose Tissue, Brown; Animals; Fluoxetine; Ligands; Male; Morpholines; Norepinephrine Plasma Membrane Transport Proteins; Positron-Emission Tomography; Rats; Rats, Sprague-Dawley; Reboxetine; Wakefulness | 2012 |
Celecoxib enhances the effect of reboxetine and fluoxetine on cortical noradrenaline and serotonin output in the rat.
Topics: Adrenergic Uptake Inhibitors; Animals; Celecoxib; Cyclooxygenase 2 Inhibitors; Dopamine; Drug Synergism; Fluoxetine; Male; Microdialysis; Morpholines; Norepinephrine; Prefrontal Cortex; Pyrazoles; Rats; Rats, Wistar; Reboxetine; Selective Serotonin Reuptake Inhibitors; Serotonin; Sulfonamides | 2012 |
Duodenal calcium transporter mRNA expression in stressed male rats treated with diazepam, fluoxetine, reboxetine, or venlafaxine.
Topics: Animals; Calcium; Calcium Channels; Cyclohexanols; Diazepam; Duodenum; Fluoxetine; Gene Expression Regulation; Ion Transport; Male; Morpholines; Rats; Reboxetine; Restraint, Physical; RNA, Messenger; Venlafaxine Hydrochloride | 2012 |
L-DOPA modifies the antidepressant-like effects of reboxetine and fluoxetine in rats.
Topics: Animals; Antidepressive Agents; Contraindications; Depression; Drug Therapy, Combination; Fluoxetine; Levodopa; Locus Coeruleus; Male; Morpholines; Motor Activity; Rats; Rats, Sprague-Dawley; Reboxetine; Treatment Outcome | 2013 |
Investigating the psychopharmacology of cognitive affective bias in rats using an affective tone discrimination task.
Topics: Affect; Animals; Anti-Anxiety Agents; Antidepressive Agents; Bias; Cognition; Cues; Diazepam; Discrimination Learning; Dose-Response Relationship, Drug; Drug Administration Schedule; Fluoxetine; Male; Morpholines; Rats; Reboxetine; Reward | 2013 |
Beneficial effects of fluoxetine, reboxetine, venlafaxine, and voluntary running exercise in stressed male rats with anxiety- and depression-like behaviors.
Topics: Analysis of Variance; Animals; Anti-Anxiety Agents; Anxiety; Cyclohexanols; Depression; Disease Models, Animal; Fluoxetine; Food Preferences; Male; Maze Learning; Morpholines; Physical Conditioning, Animal; Rats; Rats, Wistar; Reboxetine; Restraint, Physical; Running; Stress, Psychological; Sucrose; Swimming; Venlafaxine Hydrochloride | 2013 |
Antidepressants share the ability to increase catecholamine output in the bed nucleus of stria terminalis: a possible role in antidepressant therapy?
Topics: Animals; Antidepressive Agents; Antidepressive Agents, Second-Generation; Antidepressive Agents, Tricyclic; Bupropion; Citalopram; Desipramine; Dopamine; Dose-Response Relationship, Drug; Fluoxetine; Imipramine; Male; Morpholines; Norepinephrine; Rats, Sprague-Dawley; Reboxetine; Septal Nuclei; Time Factors | 2014 |
Pharmacological characterization of BDNF promoters I, II and IV reveals that serotonin and norepinephrine input is sufficient for transcription activation.
Topics: Adrenergic Agonists; Animals; Antidepressive Agents; Brain-Derived Neurotrophic Factor; Cells, Cultured; Cerebral Cortex; Fluoxetine; Hippocampus; Lithium Carbonate; Morpholines; Neurons; Norepinephrine; Promoter Regions, Genetic; Rats; Reboxetine; Serotonin; Serotonin Receptor Agonists; Transcriptional Activation | 2014 |
The effects of ifenprodil on the activity of antidepressant drugs in the forced swim test in mice.
Topics: Animals; Antidepressive Agents; Depression; Disease Models, Animal; Drug Synergism; Fluoxetine; Imipramine; Mice; Morpholines; Piperidines; Reboxetine; Swimming; Thiazepines | 2014 |
Drug-, dose- and sex-dependent effects of chronic fluoxetine, reboxetine and venlafaxine on open-field behavior and spatial memory in rats.
Topics: Adrenergic Uptake Inhibitors; Animals; Cyclohexanols; Dose-Response Relationship, Drug; Exploratory Behavior; Female; Fluoxetine; Locomotion; Male; Maze Learning; Memory, Short-Term; Morpholines; Motor Activity; Rats; Rats, Inbred Strains; Reboxetine; Selective Serotonin Reuptake Inhibitors; Sex Factors; Spatial Memory; Time Factors; Venlafaxine Hydrochloride | 2015 |
Antidepressant-like activity of a new piperazine derivative of xanthone in the forced swim test in mice: The involvement of serotonergic system.
Topics: Animals; Antidepressive Agents; Bupropion; Depressive Disorder; Fenclonine; Fluoxetine; Male; Mice; Morpholines; Motor Activity; Piperazines; Postural Balance; Reboxetine; Serotonin; Serotonin Agents; Swimming; Xanthones | 2015 |
Two Chronic Stress Models Based on Movement Restriction in Rats Respond Selectively to Antidepressant Drugs: Aldolase C As a Potential Biomarker.
Topics: Animals; Antidepressive Agents; Chronic Disease; Depressive Disorder; Disease Models, Animal; Fluoxetine; Fructose-Bisphosphate Aldolase; Green Fluorescent Proteins; Male; Morpholines; Rats, Sprague-Dawley; Reboxetine; Restraint, Physical; Selective Serotonin Reuptake Inhibitors; Serotonin and Noradrenaline Reuptake Inhibitors; Stress, Psychological | 2015 |
Fluoxetine associated with thrombocytopenia and treatment with reboxetine: 3 cases.
Topics: Adult; Antidepressive Agents; Antidepressive Agents, Second-Generation; Depressive Disorder, Major; Drug Substitution; Female; Fluoxetine; Humans; Male; Morpholines; Reboxetine; Thrombocytopenia | 2015 |
The role of 5-HT1A receptors in mediating acute negative effects of antidepressants: implications in pediatric depression.
Topics: Adrenergic Uptake Inhibitors; Animals; Antidepressive Agents; Anxiety; Behavior, Animal; Child; Depressive Disorder, Major; Fluoxetine; Humans; Mice; Morpholines; Piperazines; Pyridines; Reboxetine; Receptor, Serotonin, 5-HT1A; Selective Serotonin Reuptake Inhibitors; Serotonin 5-HT1 Receptor Antagonists; Suicidal Ideation; Suicide | 2015 |
X-ray structures of Drosophila dopamine transporter in complex with nisoxetine and reboxetine.
Topics: Animals; Antidepressive Agents; Crystallography, X-Ray; Dopamine Plasma Membrane Transport Proteins; Drosophila melanogaster; Drosophila Proteins; Fluoxetine; Morpholines; Protein Binding; Reboxetine | 2015 |
Chronic stress and antidepressant induced changes in Hdac5 and Sirt2 affect synaptic plasticity.
Topics: Adult; Animals; Antidepressive Agents; Chronic Disease; Depressive Disorder; Fluoxetine; Histone Deacetylase Inhibitors; Histone Deacetylases; Humans; Imipramine; Male; Mice, Inbred C57BL; Middle Aged; Morpholines; Neuronal Plasticity; Prefrontal Cortex; Reboxetine; RNA, Messenger; Sirtuins; Stress, Psychological | 2015 |
Effects of lobeline and reboxetine, fluoxetine, or bupropion combination on depression-like behaviors in mice.
Topics: Animals; Antidepressive Agents; Behavior, Animal; Bupropion; Depression; Drug Synergism; Drug Therapy, Combination; Fluoxetine; Immobility Response, Tonic; Lobeline; Male; Mice; Morpholines; Reboxetine | 2015 |
Antidepressants differentially affect striatal amphetamine-stimulated dopamine and serotonin release in rats with high and low novelty-oriented behaviour.
Topics: Amphetamine; Animals; Antidepressive Agents; Behavior, Animal; Corpus Striatum; Dopamine; Fluoxetine; Imipramine; Male; Microdialysis; Morpholines; Rats; Rats, Wistar; Reboxetine; Selective Serotonin Reuptake Inhibitors; Serotonin | 2016 |
Antidepressant drugs for beta amyloid-induced depression: A new standpoint?
Topics: Amyloid beta-Peptides; Animals; Antidepressive Agents; Brain; Brain-Derived Neurotrophic Factor; Depression; Fluoxetine; Immobility Response, Tonic; Ketamine; Male; Morpholines; Nerve Growth Factor; Norepinephrine; Rats; Reboxetine; Serotonin | 2017 |
Comparative efficacy and acceptability of antidepressant treatment in poststroke depression: a multiple-treatments meta-analysis.
Topics: Aged; Antidepressive Agents; Antidepressive Agents, Second-Generation; Citalopram; Depression; Depressive Disorder; Doxepin; Duloxetine Hydrochloride; Female; Fluoxetine; Humans; Male; Morpholines; Paroxetine; Patient Acceptance of Health Care; Reboxetine; Selective Serotonin Reuptake Inhibitors; Stroke; Treatment Outcome | 2017 |
Monoamine involvement in the antidepressant-like effect induced by P2 blockade.
Topics: Animals; Antidepressive Agents; Benzylamines; Biogenic Monoamines; Dose-Response Relationship, Drug; Fenclonine; Fluoxetine; Frontal Lobe; Hippocampus; Male; Mice; Morpholines; Motor Activity; Neurotransmitter Uptake Inhibitors; Purinergic P2 Receptor Antagonists; Random Allocation; Reboxetine | 2017 |
Nucleocytoplasmic export of HDAC5 and SIRT2 downregulation: two epigenetic mechanisms by which antidepressants enhance synaptic plasticity markers.
Topics: Animals; Antidepressive Agents; Down-Regulation; Epigenesis, Genetic; Fluoxetine; Histone Deacetylase Inhibitors; Histone Deacetylases; Humans; Imipramine; Male; Mice; Mice, Inbred C57BL; Neuronal Plasticity; Prefrontal Cortex; Random Allocation; Reboxetine; Sirtuin 2 | 2018 |
Effect of monoamine reuptake inhibition and α
Topics: Adrenergic alpha-1 Receptor Antagonists; Adrenergic Uptake Inhibitors; Animals; Atomoxetine Hydrochloride; Citalopram; Duloxetine Hydrochloride; Electroshock; Fluoxetine; Male; Mice; Mice, Inbred C57BL; Norepinephrine; Prazosin; Reboxetine; Seizures; Selective Serotonin Reuptake Inhibitors; Serotonin; Serotonin and Noradrenaline Reuptake Inhibitors; Sudden Unexpected Death in Epilepsy | 2019 |
Antidepressants Differentially Regulate Intracellular Signaling from α1-Adrenergic Receptor Subtypes In Vitro.
Topics: Animals; Antidepressive Agents; Citalopram; Depression; Desipramine; Fluoxetine; Gene Expression Regulation; Humans; Imipramine; Mianserin; Mice; PC12 Cells; Rats; Reboxetine; Receptors, Adrenergic, alpha-1; Signal Transduction | 2021 |
Molecular Consequences of Depression Treatment: A Potential In Vitro Mechanism for Antidepressants-Induced Reprotoxic Side Effects.
Topics: Amitriptyline; Animals; Antidepressive Agents; Antipsychotic Agents; Cell Line; Escitalopram; Fluoxetine; G2 Phase Cell Cycle Checkpoints; Gene Expression Regulation; Imipramine; Male; Mice; Micronuclei, Chromosome-Defective; Mirtazapine; Models, Biological; Olanzapine; Organ Specificity; Reboxetine; Reproduction; Signal Transduction; Spermatogenesis; Telomeric Repeat Binding Protein 1; Telomeric Repeat Binding Protein 2; Time Factors; Venlafaxine Hydrochloride | 2021 |
Monoaminergic mediation of hyperalgesic and analgesic descending control of nociception in mice.
Topics: Analgesics; Animals; Chronic Pain; Fluoxetine; Hyperalgesia; Mice; Nociception; Norepinephrine; Rats; Rats, Sprague-Dawley; Reboxetine; Serotonin | 2023 |
Treatment-Resistant Depression (TRD): Is the Opioid System Involved?
Topics: Analgesics, Opioid; Animals; Antidepressive Agents; Depression; Dose-Response Relationship, Drug; Fluoxetine; Fluvoxamine; Mianserin; Mice; Mirtazapine; Moclobemide; Naloxone; Reboxetine; Trazodone; Venlafaxine Hydrochloride | 2023 |